PPARG and metabolic dysfunction-associated steatohepatitis: TZD effects could be amplified in such PPARγ-rich fatty livers, which may be particularly relevant for the beneficial effects of TZD treatment in human patients with non-alcoholic steatohepatitis (NASH) [22,23].